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ABSTRACT 
Epigenetic machinery can regulate different biological processes via different 
mechanisms. In this thesis, we explore the effects of the epigenetic system on 
transcription and how it can differ during cellular development in different human 
cell lines models, with focus on hematopoiesis. 
Paper I, aimed to identify new roles for different epigenetic regulators in myeloid 
differentiation. We performed a CRISPR-Cas9 screen that targeted 1092 epigenetic 
factors in a model for myeloid differentiation, with the objective to uncover novel 
roles for regulatory factors that are important for differentiation in hematopoiesis. 
In our analysis, the chromodomain helicase DNA-binding 2 (CHD2) showed a 
crucial impact on megakaryocytic differentiation in the K-562 cell line model. 
 
In paper II, our aim was to identify the roles of different PHC subunits in Polycomb 
repressive complex 1 during hematopoiesis. Data mining from publicly available 
datasets showed opposite expression pattern between each PHC subunit. PHC1 
is higher expressed in early stages of myelopoiesis that is opposite to PHC2, and 
PHC3, which expression increasing with differentiation. PHC1-3 was knocked 
down individually, using siRNA in the myeloblast cell line KG-1. RNA-sequencing 
analysis after knock down for each specific PHC subunit, showed how PHC1, 2 
and 3 play different roles during development and myeloid differentiation. 
In paper III, we used the FANTOM5 database for transcription start sites (TSS) in 
a wide variety of primary cells. The study mapped the usage of alternative TSS that 
leads to exclusion of coding sequence, and exclusion of annotated protein domains. 
We demonstrated a dynamic usage of alternative TSS and their potential regula- 
tory roles in different cell lineages and development stages. We investigated the 
role of alternative TSSs for KDM2B in the Jurkat T-cell lineage and their potential 
functional consequences. 
In paper IV, our aim was to study the dynamics of 3D chromatin structure in rela- 
tion to the circadian rhythm. We demonstrated that chromosomal fiber interactions 
are organized by PARP1- CTCF activity. We showed how the 3D genome structure 
can influence circadian rhythm machinery and how the transcription activation 
and silencing are under oscillation. 
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1 INTRODUCTION 
1.1 EPIGENETICS 
The “epigenetics” term was used in 1942 by Conard Waddington to describe events 
that genetic principles could not explain those [1], and later various inexplicable 
biological phenomena added to the categories of epigenetics [2]. The “epigenetics” 
comes from Greek, and it means “outside conventional genetics” [1,3], which is a 
bridge between genotype and phenotype- a series of events that change the final 
consequence of a locus or chromosome without DNA sequence alteration dur- 
ing development [2]. In other words, the genetic information of an organism can 
express differentially in both time and space without directly affecting the sequence 
of DNA, and this can only happen with the help of epigenetic regulators [3,4]. 
 
1.1.1 Chromatin 
As the DNA in a eukaryotic cell pictured in figure 1, it organized in chromatin 
fibers with the nucleosome as a repeating unit [5,6]. In each nucleosome, 145- 
147 base pairs (bp) of DNA are wrapped around a nucleosome core: two copies 
of histone proteins H2A, H2B, H3, and H4 [5]. The linker histone H1 can assem- 
ble the nucleosome cores into higher-order structures and compact linear DNA 
by approximately 30–40 folds. Nucleosome core, linker DNA, and H1 form the 
nucleosome. The nucleosome is the main factor for DNA condensation within the 
nucleus, and DNA accessibility [5]. 
Euchromatin and heterochromatin are two well-defined states of chromatin that 
considered to be active and repressive, respectively. Facultative heterochromatin 
is a region that can switch between two states of transcription: activation and 
repression. Heterochromatin regions divided into different domains based on their 
modification and position [7]. 
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Figure 1. The organization of DNA within the chromatin structure. The nucleosome is 
the lowest level for DNA organization and folded approximately 50-fold into 30 nm fiber. 
The details structures of folding are still unclear. Figure reprinted with permission from 
the publisher [8]. 
 
 
1.1.2 Epigenetic Mechanisms 
Nowadays, all inherited changes that can alter gene expression without changes 
in primary nucleotide sequences defined as epigenetics [2,9] and there are differ- 
ent mechanisms for these alterations such as methylation of cytosine in the CpG 
dinucleotide in the DNA [10], covalent modifications of the N-terminal histone 
tails in the nucleosomes [11], remodeling of nucleosomes [12], and transcriptional 
or post-transcriptional gene silencing through the small regulatory non-coding 
antisense microRNA [13], or long non-coding RNA (lncRNA) [14]. We will dis- 
cuss some of these mechanisms in more detail in this thesis. 
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1.1.2.1 DNA Methylation 
As mentioned before, DNA methylation is one of the epigenetic mechanisms. It 
is responsible for inactivation status in one of the X-chromosome in female cells, 
and because of that, it has suggested being an epigenetic mechanism of imprinting 
[15,16]. DNA methylation is a dynamic epigenetic mark and mostly happens at 
the five positions of the cytosine position in CpG dinucleotides [17]. The preva- 
lence of CpG methylation (approximately 70-80% in mammalian genomes) occurs 
in specific regions called CpG islands (CGIs), which are rich for GC sequences 
[18]. CGIs are around 1 kb in length and are, to a high degree, non-methylated in 
germ cells, in the early embryo, and most somatic tissues. GCI’s promoters found 
in around 60% of human genes [19]. As it shows in figure 2, there are two other 
regions with different levels of methylation: located up to 2 kb away from a CGI 
named shores and within 2 – 4 kb of a CGI as shelves [20]. There are open sea 
areas with more distance from CGI, which are not in figure 2. 
 
 
 
Figure 2. CpG iIsland (CGI) promoter. CGI, shore, and shelf pictured in the figure for the 
active and silenced situation. Figure reprinted with permission from the publisher [19]. 
Copyright to Cold Spring Harbor Laboratory Press. 
 
 
There are three different DNA methyltransferases enzymes: DNMT1, DNMT3A, 
and DNMT3B. DNMT1 is maintaining DNA methylation patterns during mitosis, 
DNMT3A and DNMT3B are de novo methyltransferases. In normal cells, approxi- 
mately 3-6% of cytosines are methylated. In the cancer cells, the aberrant DNA 
methylation can take place. Hypomethylation in the genome of cancer cells can 
cause genome instability [21]. There are two pathways for DNA demethylation: 
active and passive [22]. In the active pathway, the ten-eleven translocation (Tet) 
proteins family (TET1, TET2, and TET3) can change 5-methylcytosine (5mC) to 
5-hydroxymethylcytosine (5hmC) [22,23]. It followed by the next steps in which 
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5hmC, undergoes further oxidation into 5-formylcytosine (5fC) and 5- carboxylcyto- 
sine (5caC), which finally converted to unmethylated cytosine. In order to facilitate 
their functions, TET proteins need ferrous iron (Fe2+) as an essential cofactor and 
2-oxoglutarate (2-OG) as an obligatory co-substrate [22]. Oxidized methylcytosines 
(oxi-mCs) enriched at promoters, enhancers, and gene bodies which, can have 
effects on gene expression [24]. Passive demethylation happens through replication 
during cell division. This can happen in the absence or inhibition of DNMT1 [19]. 
 
1.1.2.2 Histone Post Translational Modifications 
As mentioned earlier, DNA packed with the help of histones proteins into chromatin. 
Histones can obtain different post-translational modifications on their N-terminal 
tails, such as methylation, acetylation, sumoylation, phosphorylation, ubiquitina- 
tion, and ADP-ribosylation [25,26]. In table 1, some of these modifications and 
their functions summarized. 
 
 
Different Classes of Modifications Identified on Histones 
 
Chromatin Modifications Residues Modified Functions Regulated 
Acetylation K-ac Transcription, Repair, Replication, 
Condensation 
Methylation K-me1 K-me2 K-me3 Transcription, Repair 
Methylation R-me1 R-me2a R-me2s Transcription 
Phosphorylation S-ph T-ph Transcription, Repair, Condensation 
Ubiquitylation K-ub Transcription, Repair 
Sumoylation K-su Transcription 
ADP ribosylation E-ar Transcription 
Deimination R>Cit Transcription 
Proline Isomerization P-Cis> P-trans Transcription 
Table 1. Different classes of modifications identified on the core histones and their modi- 
fied residues. The table adapted with permission from the publisher [26]. 
 
 
Histone modifications can classify into two different groups according to their 
effects on transcription: activators or repressors. However, some modifications can 
act as an activator or repressor under different situations, for example, methyla- 
tion at lysine 9 at histone H3 has a negative effect on the promoter and positive 
in the coding region [27,28]. 
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SirT2 (ScSir2) H4K16 
1.1.2.3 Histone-Modifying Enzymes 
Most of the histone modifications are dynamic processes. In table 2, some of the 
histone-modifying enzymes and their target residues summarized. 
 
Histone-Modifying Enzymes 
 
Enzymes that Modify Histones Residues Modified 
 
 
Acetyltransferases 
HAT1 H4 (K5, K12) 
CBP/P300 H3 (K14, K18) H4 (K5, K8) 
H2A (K5) H2B (K12, K15) 
PCAF/GCN5 H3 (K9, K14, K18) 
TIP60 H4 (K5, K8, K12, K16) 
H3 K14 
 
Methyltransferases 
G9a H3K9 
CLL8 H3K9 
MLL1 H3K4 
SET1A H3K4 
SET1B H3K4 
ASH1 H3K4 
EZH2 H3K27 
RIZ1 H3K9 
 
Demethylases 
Lsd1/BHC110 H3K4 
JHDM1a H3K36 
 
Deacetylases 
 
Table 2. Histone-Modifying Enzymes and their modified residues. The table adapted with 
permission from the publisher [26]. 
 
 
Two main functions considered for histone modifications: implementing global 
chromatin environments and coordinating DNA-based biological functions. Histone 
modifications not only can affect each other, but they can also communicate with 
DNA methylation [26]. 
 
 
 
 
5 
  
Histone acetyltransferase (HAT) enzymes transfer acetyl group from acetyl-CoA 
to specific lysine residues, which can result in a chromatin structure diffusion, 
which gives accessibility to transcriptional factors [29]. Based on their cellular 
localization, HATs classified into two groups [30]. The nuclear localization has seen 
in type A HATs; there are several transcriptional factors such as p600, CLOCK, 
and TAF1 among this group [29]. Type B HATs acetylate the newly synthesized 
histones, and they are localized in the cytoplasm [29]. HATs family members play 
a role in normal hematopoiesis and malignancies, as pictured in figure 3 [29]. 
 
 
 
Figure 3. Histone acetyltransferases (HATs) regulate both normal and malignant hemat- 
opoiesis. HATs generate H3K27ac in, active enhancers. There is crosstalk between histone 
acetylation and methylation in hematopoiesis. HDAC inhibitors used for the therapy in 
malignant hematopoiesis. Figure reprinted with permission from the publisher [29]. 
 
 
Lysine or arginine residues in histones can accept different modifications. They can be 
methylated. Lysine methylation of histones creates specific signals depending on the 
residue. Lysine can be acetylated, which can promote gene activation [31-33]. Most 
of the characterized histone methyltransferases contain a SET domain, and typically 
they are specific about their targets on histone proteins [25]. Arginine methylation 
can regulate transcriptional activation [34]. The enzymes associated with adding or 
removing of histone methylation are key regulators for cell development and linked 
with human diseases [25]. For example, a lysine‐specific histone demethylase 1 (LSD1) 
is necessary for the differentiation of hematopoietic cell lines in human [35]. The 
overexpression of several histone demethylases has reported in various cancers [35]. 
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1.1.2.4 Polycomb-group Proteins 
Polycomb group (PcG) proteins are transcriptional repressors that can modify 
histone proteins and their activities [36]. The PcG complexes play critical func- 
tions in regulating cell proliferation, self-renewal, and differentiation in several 
tissues, including blood cells [37]. Polycomb Repressive Complex 1 (PRC1) and 
2 (PRC2) belong to nuclear complexes [37,38]. In table 3, each complex and its 
subunits are listed. 
 
PRC2 complex catalyzes the transcriptionally repressive di-methylation and tri- 
methylation of lysine 27 on histone H3 (H3K27me2/3). The catalytic subunit of 
PRC2 is the enhancer of zeste homolog 2 (EZH2) subunit. EZH2 binds to sup- 
pressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED). All 
these subunits together constitute the core unit of the enzymatically active PRC2 
complex [37,38] which are necessary for PRC2 integrity and PRC2-mediated 
H3K27 methylation [39]. The other PRC2 subunits are the histone deacetylases 
HDAC1, HDAC2, histone-binding proteins retinoblastoma-associated protein 46 
(RbAp46), and RbAp48, that are not essential for its activity [38]. 
 
 
 
 
PRC1 PRC2 
 
TrxG 
Subunit Molecular Function Subunit Molecular Function Subunit Molecular Function 
 
CBX Chromodomain binds H3K27me3 
 
EZH2 SET domain methyl- ates H3K27 
 
ASH1L SET domain methyl- ates H3K36 
 
PCGF Binds DNA and com- pacts chromatin 
 
SUZ12 Enhances E(z) HMTase activity 
MLL 
C-ter 
SET domain methyl- 
ates H3K4 
 
PHC 
 
SAM domain 
self-associates 
 
EED 
Enhances E(z) 
HMTase activity 
binds H3K27me3 
 
MLL 
N-ter 
 
Required for H3K27 
acetylation by CBP 
 
RING1A 
and 
RING1B 
Ubiquitylates 
H2AK118 (K119 in 
vertebrates), com- 
pacts chromatin 
 
RbAp46 
and 
RbAp48 
 
Binds histones and 
SU(z)12 
 
BRD4 
Bromodomains 
bind acetylated Lys 
BRD4 phosphory- 
lates Pol II CTD at 
Ser2 
Table 3. Polycomb repressive complex 1 (PRC1), Polycomb repressive complex 2 (PRC2), 
and Trithorax group (TrxG) proteins subunits and their functions. The table adapted with 
permission from the publisher [40]. 
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As the schematic figure 4 shows, in mammalian cells, PRC1 complexes are hetero- 
geneous and classify into two groups based on PcG RING finger proteins (PCGFs): 
PRC1.2 and PRC1.4 as canonical PRC1 complexes and PRC1.1, PRC1.3, PRC1.5, 
and PRC1.6 belong to uncanonical category [36,41]. 
 
 
 
Figure 4. Subunit content in canonical and non-canonical PRC1 complexes. The RING1A/B 
and PCGF1-6 form the core subunits in PRC1 complexes. In canonical PRC1, one PHC 
and one CBX protein incorporate. There are incorporations of RYBP/YAF2 and some other 
subunits in noncanonical PRC1. Figure reprinted with permission from the publisher © 
2019, Di Carlo V, et al. Originally published in the Journal of Cell Biology. https://doi. 
org/10.1083/jcb.201808028 
 
 
PRC1 catalyzes mono-ubiquitylation on lysine 119 (K119) of histone H2A 
(H2AUb119), which also is a repressive histone marker [38]. H2AK119Ub1 can 
promote compaction in chromatin, which leads to inhibition of transcriptional 
elongation and gene silencing [38]. 
 
The core PRC1 complex consists of RING1A/B and PcG ring finger (PCGF) pro- 
teins (Figure 4). Each PRC1 complex has a specific PCGF1-6 subunit: NSPC1/ 
PCGF1, MEL-18/PCGF2, PCGF3, BMI-1/PCGF4, PCGF5, or MBLR/PCGF6 [36]. 
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The ubiquitin E3 ligase complex contains different PcG proteins, such as RING1/ 
Ring1A, RING2/Ring1B, and BMI-1/Bmi-1 [42]. The catalytic subunits of PRC1 
are RING1A and RING1B [38,42]. At the N-terminal of the RING finger proteins, 
there is a specific type of Zn2+-binding motif, Cys3HisCys4. There is a Ring fin- 
ger and WD40 associated Ubiquitin-Like (RAWUL) domain at their C-terminal. 
The RING finger motifs pair and use E3 ubiquitin ligases and the RAWUL motifs 
as binding platforms for other PRC1 subunits [41]. The canonical PRC1.2 and 
PRC1.4 complexes are the only ones with Polyhomeotic homolog proteins (PHC) 
and chromobox homolog (CBX) proteins [36]. 
Different mechanisms have suggested for Polycomb complexes recruitment to 
their specific targets [43]. The PRC1 recruitment to its target can be dependent or 
independent on pre-existing trimethylation (H3K27me3) marks [44]. The CBX 
subunit in PRC1 recognizes target sites with H3K27me3, which leads to ubiq- 
uitination on H2AK119 [43]. It has also suggested that transcription factors or 
lncRNA could participate in Polycomb recruitment [43,45]. The noncanonical 
PRC1s (PRC1.1, 2, 5, and 6) have the RING1- and YY1-binding protein (RYBP) 
subunits that are involved with H3K27me3-independent recruitment [46]. For the 
independent pathway, the Kdm2b suggested to recognize CpG islands and help 
with PRC1 recruitment [47,48]. 
As mentioned before (Figure 4), in mammalian systems, there are multiple PRC1 
and PRC2 complexes that are encoded by multicopy PcG genes that give them a 
diversity of function [49]. In addition, PcG machinery also linked to X inactivation 
[50], parent-of-origin imprinting [51], and cancer epigenetics [52]. 
 
The PcG complexes can lead to transcription repression by removing HATs from 
their target genes [53]. PRC2 depletion can lead to increasing the H3K27 acetyla- 
tion globally, which is catalyzed by p300 and CBP. PRC1 are very dynamic com- 
plexes. They can evolve between different cell stat developments [41]. Chromatin 
locations that enriched with PRC1 and PRC2 complexes are dispersed throughout 
euchromatin and can overlap with each other’s but rarely find in heterochromatin 
areas and silenced domains [41,54]. The Polycomb complexes silence essential 
target genes for the cell maintenance identity during cell states transitions [41]. 
 
1.1.2.5 Trithorax Group (TrxG) 
The PcGs are not the only large multiprotein complexes that can change chroma- 
tin with catalyzing covalent modifications on histones and leading to chromatin 
structural changes. Silencing and activation need to be in dynamic balance [40]. 
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Trithorax protein group (TrxG) is responsible for activation, which acts antagonis- 
tically from PcGs [40]. For instance, histone lysine methylation at Lys4 (H3K4) 
and Lys36 of histone H3 (H3K36), which catalyzed by Trx and Absent, small and 
homeotic discs 1 (Ash1) respectively, inhibits PRC2-mediated trimethylation at 
histone H3 lysine 27 (H3K27me3) [55,56]. In table 3, the main subunits for each 
complex described. 
Another layer of antagonism operation for PcG and TrxG is through RNA poly- 
merase II (Pol II) [40]. Histone lysine ubiquitylation of histone H2A mediated by 
the PRC1 complex, and it colocalizes with Pol II. This ubiquitylation is necessary 
for the existence of an unproductive, ‘poised’ Pol II with Ser5-phosphorylation, 
at bivalent genes in embryonic stem cells, that might prevent elongation step 
[57]. Although, phosphorylation at Ser2 in Pol II can occur via the TrxG protein 
bromodomain-containing 4 (BRD4) and may promote elongation [58]. 
 
PcG and Trx have opposite effects on transcription [40]. PRC1 promotes chroma- 
tin compaction [59], whereas Trx promotes an open configuration. The H3K27 
acetylation facilitated by Trx can neutralize the positive charge of Lys and disrupt 
histone-DNA contacts [60] [40]. 
 
1.1.2.6 Non-coding RNA 
Lots of studies have shown that non-coding RNAs (ncRNA) play an important role 
in epigenetic regulation [61]. There are different categories of ncRNA. They can 
categorize based on their size. Long non-coding RNAs (lncRNA) are longer than 
200 nucleotides, and small non-coding RNAs are shorter than 200 nucleotides [62]. 
 
Long non-coding RNAs (lncRNAs) are associated with different mechanisms. 
They can regulate gene expression, coordinate chromatin structure, and involve 
in mRNA stability [63]. The lncRNAs are involved in cellular proliferation and 
differentiation and can act as oncogenes in different cancers [64]. 
MicroRNA is another group of ncRNAs that containing approximately 22 nucleo- 
tides, which can cleave from 70-100 nucleotide hairpin precursors and can hybrid- 
ize with complementary mRNA target genes and inhibit their functions [13]. 
MicroRNAs have regulatory roles and are responsible for post-transcriptional 
gene silencing [65]. MicroRNAs dysregulation has found in several solid tumors 
and hematologic malignancies [66]. 
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1.1.2.7 Chromatin Remodelers 
ATP-dependent chromatin remodelers contain different assembled complexes that 
each of them has an ATPase subunit, which belongs to the SNF2 protein super- 
family [67]. These enzymes depend on the existence of other conserved domains 
that are categorized into the mating type switching/sucrose non-fermenting (SWI/ 
SNF), inositol (INO80), chromodomain helicase DNA-binding (CHD), and imita- 
tion switch (ISWI) families [67]. These remodelers are specific for cell-type and 
developmental-stage [68]. In vitro studies showed that they all increase nucleo- 
some mobility [68]. 
 
1.1.2.8 Chromodomain Helicase DNA-binding (CHD) Family 
CHD family has structural and functional domains that play roles in potential 
physical interactions with nucleosomes: (a) tandem chromodomains (chromatin 
organization modifier) located in the N-terminal region, which is in common 
with other chromatin-associated proteins such as Polycomb and heterochromatin 
protein 1 (HP1). (b) In the central region of the protein structure, the helicase/ 
ATPase domain, which has a high similarity with the SWI2/SNF2 ATPase. (c) The 
C-terminal DNA-binding domain, with a preferential to bind DNA regions with 
A+T-rich sequences [67,69]. 
The CHD protein family has nine members and three subfamilies [69]. The sub- 
family I consists of CHD1 and CHD2, which contain all the common domains for 
the CHD family. The CHD3 and CHD4 belong to subfamily II which they do not 
have the DNA-binding domain, but they have a double plant homeodomain (PHD) 
zinc-finger domains at their N-terminal. The rest of the CHD members belong to 
subfamily III. The majority of this subfamily members contain a conserved ter- 
minal hairpin (TCH) motif or a DNA binding domain named SANT domain [70]. 
These remodelers considered as either transcriptional activators or repressors [70]. 
These families with more structure domains showed in figure 5. 
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Figure 5. Schematic representation of all known CHD 1-9 proteins in human and their 
structural domains. The two truncated chromodomains in N-terminal, the SNF2-like helicase- 
ATPase domain at the center, and DNA-binding domain in C-terminal are the common CHD 
domains pictured in the figure. Figure reprinted with permission from the publisher [69]. 
 
 
It has shown that the CHD family can change nucleosome composition or its loca- 
tion [69]. CHD1 and CHD2 have a role in transcription activation and elongation 
as well as they have interactions with different elongation factors, transcription 
factors, activators, and co-activators [69]. 
 
1.1.3 3D Genome Organization 
In higher eukaryotes, the genome organized non-randomly in the three-dimensional 
(3D) space of the nucleus. Instead, in the interphasic nucleus, individual chromo- 
somes occupy specific delimited regions called “chromosome territories” (CT) 
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[70-73], which constitute a significant feature of nuclear architecture. In order to 
achieve the necessary degree of compaction to fit within these areas, the chromatin 
fiber needs to condense by looping into itself [74]. This organization within the 
nuclear space has functional implications in the regulation of gene expression and 
in other nuclear processes. Thus, the radial position of chromosomes and genes 
in the nucleus is cell-type and tissue-specific and is often altered in cancer and 
disease cells [74]. 
 
Chromosome territories further organized into sub-chromosomal domains. 
Chromosomes first organized into two different types of compartments: A (“active”) 
and B (“inactive), in accordance with their transcriptional status and the degree of 
chromatin compaction. Within those compartments, chromatin further organized 
into topologically associating domains (TADs), self-interacting domains from 
several hundred kb up to 1-2 MB in size, with an average of around 800 kb [73] 
in mammals. TADs formed with the help of specific architectural proteins like 
CCCTC-binding factor (CTCF) and cohesin, which often found at their boundaries 
[75]. Likewise, chromosome territories, TADs can differ in structure following 
gene activation in different cell types or conditions [76]. 
 
1.1.3.1 Active and Inactive Domains of Genome Organization 
The non-random organization of the genome has a direct correlation with gene 
density and transcriptional activity. In general, genes placed in gene-dense regions 
tend to be more active in comparison to genes located in gene-poor regions. This 
placement results in megabase sized domains, which switch between high and 
low transcriptional activity [77]. 
 
A clear example of that is the nuclear envelope, which has a regulatory role in 
transcription and gene regulation [74]. In most higher eukaryotes, the nuclear 
periphery is enriched in condensed heterochromatin and has a connection with 
transcriptional repression [73]. Those domains directly associated with the nuclear 
lamina are called lamina-associated domains (LADs) [78]. LADs contain gene- 
poor regions and contain developmentally repressed genes that emerge during 
differentiation. LADs can vary in their size, from approximately 10 kb to a few 
megabases [74]. Besides, LADs boundaries enriched for binding sites for the 
insulator protein CTCF [74]. 
 
LADs highly overlap with other heterochromatin domains enriched for histone 
H3 lysine 9 di-methylation (H3K9me2), named large organized chromatin lysine 
modifications (LOCKs). LOCKs and LADs can change in size during develop- 
ment, present cell-type specificity, and lose in cancer cells [78,79]. 
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1.1.4 Transcription and Promoters 
The number of different transcripts that one gene can have is unclear. There are 
less than 20000 genes in human that are encoding more than 80000 protein-coding 
transcripts, and this suggests there are extensive regulation mechanisms at the 
transcriptional, translational, and post-translational levels [80]. There are four 
different regulatory mechanisms for alternative transcription: a) alternative tran- 
scription initiation, b) alternative translation initiation, c) alternative splicing, and 
d) alternative polyadenylation [80,81]. The alternative transcription initiation is 
the outcome of using alternative promoters and transcription start sites (TSSs) in 
protein-coding transcripts [80]. In mammalian genomes, more than 70% of genes 
have multiple polyadenylation sites, more than half of genes have alternative TSSs, 
and approximately all genes have alternative splicing [81]. 
There are two classes of mammalian promoters: conserved TATA box-enriched 
promoters and CpG-rich promoters [82]. The TATA-box promoters are usually 
associated with tissue-specific genes and highly conserved across species, and 
they are a minority in both mouse and human [82]. The board distribution of CpG 
islands represents the majority of promoters in mammalian [82]. 
 
1.1.4.1 Alternative Transcription Start Site (TSS) 
The regulation for using alternative AUG and translation isoform depends on the 
availability of translation initiation factor complex [83]. The binding of different 
transcription factor complexes at the regulatory elements in promoter sequences 
can result in more than one RNA transcript, which can lead to different transcrip- 
tion isoforms [83] (Figure 6). 
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Figure 6. Mechanisms of isoform formation. Different transcription start sites (TSS), 
and alternative promoters, alternative splicing, and alternative translational start sites can 
result in different isoforms. Figure reprinted with permission from the publisher [83]. This 
research originally published in the International Journal of Hematology. Grech G, et al., 
Expression of different functional isoforms in haematopoiesis. Int J Hematol. 2014, 99(1), 
pp 4–11. The original publication is available at https://link.springer.com/journal/12185 
 
 
Alternative transcript isoforms are essential for biological regulation, and their 
misexpression linked with different diseases, including cancer [81]. It has shown 
that alternative transcript isoform choice has tissue-specific regulation in the 
human genome, which is affecting approximately half of multi-exonic genes [81]. 
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1.2 HEMATOPOIETIC SYSTEM 
1.2.1 Hematopoiesis 
The most regenerative tissue in human body is the blood which, can produce up 
to 1012 cells per day [84]. Hematopoietic stem cells (HSCs) have self-renewal 
capacity. As a result of this capacity, both the common myeloid progenitor (CMP) 
and the common lymphoid progenitor (CLP) are generated from HSCs [85,86]. 
 
The adult hematopoietic system consists of two separate lineages: myeloid and 
lymphoid. The lymphoid lineage includes the B, T, and natural killer (NK) cells. 
The myeloid lineage is more diverse and includes monocytes, macrophages, eryth- 
rocytes, megakaryocytes, granulocytes (neutrophils, eosinophils, and basophils), 
and mast cells. [86,87]. (Figure 7) 
 
Figure 7. Hematopoiesis. Hematopoietic stem cells give rise to two major cell lineages, 
the myeloid and lymphoid. HSC, hematopoietic stem cell; MPP, multipotent progenitor; 
CMP, common myeloid progenitor; CLP, common lymphoid progenitor; GMP, granulocyte- 
monocyte progenitor; MEP, megakaryocyte-monocyte progenitor. Figure reprinted with 
permission from the publisher [87]. 
 
 
The formation of blood cells or hematopoiesis occurs in the bone marrow niche 
[88]. A hematopoietic stem cell has two specific functions: self-renewal capacity 
and multilineage differentiation potential. Asymmetric division can provide an 
identical stem cell and a more mature cell [87,89]. 
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1.2.2 Epigenetics Regulation in Hematopoiesis 
Hematopoiesis is a good model to study epigenetic mechanisms. For example, DNA 
methylation and different gene expression regulation are so critical for cell-fate and 
HSC differentiation into different blood lineages [90]. DNA methyltransferases 
enzymes play a critical role in hematopoiesis. DNA methylation increases dur- 
ing lymphoid differentiation and decreases during myeloid lineage development 
[90]. DNMT3A and DNMT3B are involved in HSC renewal and differentiation. 
DNMT3B has more specific expression patterns than DNMT3A and is expressed 
only in hematopoietic stem cell and hematopoietic progenitor cells (HPCs) [91,92]. 
As mentioned before, histone modifications are epigenetic regulatory factors. Their 
role in chromatin status and their enzyme modifiers are essential in the regulation 
of hematopoiesis differentiation; their dysregulation has reported in different types 
of leukemia [92]. As it comes before, both PRC1 and PRC2 are important for HSC 
self-renewal and hematopoiesis regulation [93]. 
 
Another mechanism that is important for regulation is transcription factors and 
cytokine receptors. The levels of the transcription factors differ in different cell 
lineages. For example, GATA-2 expression is in all intermediate myeloid progeni- 
tors, or stoichiometry between GATA-1 and PU.1 is important for megakaryocytic- 
erythroid (MegE) and granulocytic-macrophage (GM) lineages commitment [94]. 
Different types of leukemia can occur depending on the level of hematopoietic 
cell differentiation when first neoplastic transformation happens, and based on 
which PcG gene is involved [37]. The transcriptional activation of PcG-targeted 
genes has shown to correlate with methylation- to-acetylation change in MLL- 
AF9-transduced HSC cells [29]. 
 
1.2.3 Epigenetics Regulation in Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is an aggressive clonal malignancy characterized 
by the accumulation of abnormally differentiated or poorly differentiated cells in 
bone marrow due to somatic genetic mutations in hematopoietic progenitor cells 
that change standard mechanisms of proliferation, self-renewal, and differentiation 
[66,95]. The most common type of acute leukemia in adults is AML, which is the 
leading cause of death among leukemias in the United States [96]. 
 
The data from the Cancer Genome Atlas AML sub-study revealed that muta- 
tions involved in AML can classify into one of these nine classifications: DNA 
methylation-related genes, transcription factor fusions, myeloid transcription fac- 
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tor genes, the NPM1 gene, chromatin-modifying genes, tumor suppressor genes, 
cohesin complex genes, signaling genes, and spliceosome complex genes [97]. 
 
The epigenetic aberrations have a significant role in AML occurrence [92]. Several 
mutations in epigenetic regulators have detected, for example, DNMT3A with 
26% to 16%, Isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes with 33% to 
15% and Ten-eleven translocation 2 (TET2) enzyme with 23% to 7% are the most 
common mutations in epigenetic regulators in AML [92]. 
 
Another layer of dysregulation in AML occurs in histone modifier enzymes. 
Mutations in EZH2, ASXL1 (additional sex-comb like-1), and MLL (mixed-lineage 
leukemia) have reported in different patients studies [98,99]. MLL has reported 
as the most dysregulated histone modifier in AML [100]. 
As mentioned before, the nuclear organization is important for gene expression regu- 
lation [101]. Different epigenetic regulators are involved in 3D nuclear structures, 
and their dysregulation reported in different cancers and especially AML. Cohesin 
is one of these regulators. All the members of the cohesin complex reported being 
mutated in AML patients [102,103]. In AML, mutations in cohesin can associate 
with mutations in TET2, DNMT3A, RUNX1, or NPM1 [104]. 
Besides, hypermethylation that can cause silenced genes is involved in myeloid 
malignancies as both prognostic markers and therapeutic targets [66]. Therefore 
genome-wide epigenetic profiling is critical for understanding AML to have a 
more accurate molecular therapy [66]. 
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1.3 CIRCADIAN RHYTHM MACHINERY 
The term “circadian” comes from the Latin “circa diem” which means “about a 
day”. Circadian rhythms defined as the physiological and biochemical properties 
of the human body that recur with approximately 24-hour cycles [105]. Sleep/wake 
cycles, for instance, represent a manifest of this internal timing [106]. Circadian 
clocks exist in most of the life forms, giving the organism the ability to predict 
daily variations in the environment and have appropriate physiological responses 
to adapt to it [107]. 
In mammals, the master circadian clock situated at the suprachiasmatic nucleus 
(SCN), located at the anterior part of the hypothalamus, and it controls oscillat- 
ing circadian rhythms of many physiological and behavioral responses [108]. 
Circadian clocks need to readjust daily by external time cues or Zeitgebers [106]. 
At the SCN, light is the predominant zeitgeber, while at the peripheral organs, 
feeding-fasting rhythms are more dominant [109]. 
 
1.3.1 Circadian Clock Regulation 
The circadian clock is under the control of negative transcriptional and translational 
feedback loops [110]. Two basic helix-loop-helix (bHLH) transcription factors in 
mammals, Circadian Locomotor Output Cycles Kaput (CLOCK), and Brain and 
Muscle ARNT-Like 1 (BMAL1), constitute the positive limb of the feedback loop. 
Upon activation, these transcription factors heterodimerize and bind to conserved 
E-box regulatory sequences in their target promoters [111] to promote transcrip- 
tional activation of clock-controlled genes (CCGs) such as the Cryptochrome- 
encoding genes (Cry1-2), and Period-encoding genes (Per1-3) [112]. CRY and 
PER proteins make then a complex in the cytoplasm that translocate back to the 
nucleus and can inhibit CLOCK: BMAL1-mediated gene expression [111,112], 
conferring the negative limb of the feedback loop. This regulation by CLOCK: 
BMAL1 heterodimers affects a broad range of physiological functions [113]. 
The circadian machinery controls cellular transcription to provide proper adaptation 
to the environment regarding the diurnal cycle. Between 2-30% of all mammalian 
transcripts undergo circadian oscillation depending on cell or tissue type [113,114]. 
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1.3.2 Circadian Clocks and Epigenetics Regulations 
There have been studies showing that not only DNA methylation but also histone 
post-translational modification (PTMs) can associate with the circadian machinery 
[115]. Specific epigenetic remodelers are under the coordination of the molecu- 
lar clocks. For instance, histone H3K4-specific methyltransferase mixed-lineage 
leukemia 1 (MLL1) interacts with CLOCK: BML1 complex to promote oscillat- 
ing circadian transcription [116,117]. Furthermore, the circadian machinery can 
affect chromatin architecture and DNA topology [115]. Chromatin conformation 
capture (3C-based) techniques showed that circadian chromatin loops occur to 
control specific promoter-enhancer interactions that regulate circadian transcrip- 
tion [118,119]. 
CLOCK has intrinsic histone acetyltransferases (HAT) activity which, is neces- 
sary for its gene expression and circadian function [113,120,121] and can help it 
to act as a chromatin modifier [122]. This function can be enhanced by BMAL1, 
its heterodimer partner [120]. 
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2 AIM OF THE THESIS 
The overall aims for this thesis were to study the epigenetic and transcriptional 
regulation of cellular development and differentiation. 
 
Study I: 
Investigate novel roles for epigenetic factors during differentiation of hemato- 
poietic cells 
 
Study II: 
Identify the role of Polyhomeotic homolog proteins (PHC) subunits of 
Polycomb repressive complex 1 during myeloid differentiation 
 
Study III: 
To study the potential roles for alternative Transcription Start Sites (TSS) on 
protein domains exclusion 
 
Study IV: 
To understand the role of 3D chromatin structure on transcription 
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3 MATERIALS AND METHODS 
This section provides a brief description of some of the specific methods used in 
studies I-IV. For more details and remaining methods please see the materials and 
methods for each study. 
 
3.1 Cell Culture 
The human blood cell line K-562 (ATCC® CCL-243™), established from a 53-year- 
old female with chronic myelogenous leukemia in terminal blast crisis, was cultured 
in Iscove’s Modified Dulbecco’s Medium (IMDM) (12440061, ThermoFisher 
Scientific) supplemented with 10% fetal bovine serum (10270106, ThermoFisher 
Scientific). K-562 cell line was used for transfection and differentiation study in 
paper I. Since we were not able to establish stable Cas9 expression in HL-60 or 
U-937 cell lines. 
The KG-1 cell line (ATCC® CCL-246), established from a 59-year-old Caucasian 
male with erythroleukemia that evolved into acute myelogenous leukemia, was 
cultured in RPMI 1640 medium (21875034, ThermoFisher Scientific) supplemented 
with 10% fetal bovine serum in paper II. 
Jurkat, Clone E6-1 (ATCC® TIB-152), established from the peripheral blood of a 
14-year-old boy, was cultured in RPMI 1640 medium (21875034, ThermoFisher 
Scientific) supplemented with 10% fetal bovine serum in paper III. 
Human colon cancer cell line HCT116 cell line (ATCC® CCL-247™), established 
from a male with colorectal carcinoma, was cultured in McCoy’s 5A medium 
(ThermoFisher Scientific, 26600023) supplemented with 10 % fetal bovine serum 
and 1% penicillin-streptomycin (15140122, ThermoFisher Scientific). Serum shock 
treatments were performed [123]. HCT116 cells were cultured with serum-rich 
medium with 50% horse serum (16050122, ThermoFisher Scientific, 16050122) 
for 2 hours. Cells were cultured with serum free McCoy’s 5A medium for indi- 
cated periods in paper IV. 
 
Human female embryonic stem cells (HS181) (HESCs) were cultured on irradi- 
ated male feeder fibroblasts [124], and human embryoid bodies (HEBs) were 
differentiated in vitro from HS181 cells in paper IV. 
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3.2 Colony Forming Unit Assay 
In vitro colony Forming Unit (CFU) Assay can be used to measure and quantify 
the ability of proliferation, differentiation and colony forming capacity [125]. 
 
To better understand the effect of the knock out of our target gene (CHD2) in K-
562 cell line, we performed CFU assay. We used semi-solid methylcellulose 
medium (MethoCult™ H4034 Optimum, StemCell Technologies) in the presence 
of all cytokines including recombinant human stem cell factor (SCF), recombinant 
human erythropoietin (EPO), recombinant human granulocyte colony-stimulating 
factor (G-CSF), recombinant human interleukin 3 (IL-3), and recombinant human 
granulocyte-macrophage colony-stimulating factor (GM-CSF). In each sample, 
approximately 1000 cells were resuspended to 1mL of Iscove’s Modified Dulbecco’s 
Medium (IMDM) with 2% Fetal Bovine Serum (07700, StemCell Technologies). 
The cell mixture was vortexed vigorously and seeded on a 35 mm dish (27100, 
StemCell Technologies). The dishes were kept in humidity at 37 °C and colonies 
were counted after 11 days using an inverted microscope. 
 
3.3 CRISPR-Cas9 Screen 
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR- 
associated (Cas) technique is a new and powerful method for genome manipula- 
tion. CRISPR-Cas9 is an evolved defense system in bacteria and archaea against 
viruses and plasmids [126]. It depends on small RNAs for sequence-specific 
detection and silencing of foreign nucleic acids [126]. CRISPR/Cas9 consists  
of two components: single guide RNA (sgRNA) and Cas9 endonuclease [127]. 
 
The sgRNA has two parts: a constant part which forms a stem-loop scaffold for 
binding to Cas9, and a 20-nt part at 5’-end for complementary binding at differ- 
ent target DNA sites [127]. 
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Figure 8. Schematic view for Clustered Regularly Interspaced Palindromic Repeats 
-Associated Proteins9 (CRISPR-Cas9) editing system and compare it with CRISPR- 
from Prevotella and Francisella 1 (Cpf1). In Cpf1, protospacer adjacent motif (PAM) is 
a T-rich region (5’-TTTN-3’) in comparison with a G-rich region (5’-NGG-3’) for Cas9. 
In the Cpf1 editing system, cohesive overhangs create after double-strand breaks (DSBs) 
compare with blunt ends in the Cas9 system. In both systems, the DSBs repair through 
Homology-directed repair (HDR) and nonhomologous end-joining (NHEJ). Figure reprinted 
with permission from the publisher [128]. 
 
 
CRISPR/Cas9 can be used for loss of function, repressing or activating the expres- 
sion of a specific gene [127,129]. CRISPR/Cas9 method is easier and more efficient 
compare to other gene editing technologies, e.g. zinc-finger nucleases (ZFNs) and 
transcription activator-like effector nucleases (TALENs). Unlike other methods 
that bind to specific DNA sequence with protein-DNA recognition, CRISPR/Cas9 
binds to the target by the help from the 20-nt sequence at the 5’ end of sgRNA as it 
has shown in the figure 8. The CRISPR/Cas9 is also cheaper than other techniques 
but there are some drawbacks as well, for example on/off-target efficiency [127]. 
Different algorithms are used to overcome the efficacy and specificity in design- 
ing a good sgRNA. Another way to have lower off-target is to use CRISPR from 
Prevotella and Francisella 1 (Cpf1) protein instead of Cas9 because it only needs 
mature crRNAs (CRISPR RNA) for targeting, while Cas9 system requires both 
tracrRNA (transactivating crRNA) and crRNA [127]. And as it pictured in figure 
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8, Cpf1 generating cohesive ends in compare with blunt ends in Cas9 which also 
helps to increase the efficiency of its insertion [128]. 
In the first part of paper I, K-562 cell line with a stable Cas9 expression was used 
to study a library targeting 1092 epigenetic factors. The CRISPR_Cpf1 was used 
for gene-specific study in paper I. 
 
3.4 siRNA Transfection 
The Neon™ Transfection System 100 µL Kit (MPK10096, ThermoFisher Scientific) 
was used for siRNA transfection in paper II and III. 
 
ON-TARGETplus Human PHC1 (1911) siRNA SMARTPOOL (L-011850-00- 
0005, Horizon Discovery); ON-TARGETplus Human PHC2 (1912) siRNA 
SMARTPOOL (L-021410-00-0005, Horizon Discovery); ON-TARGETplus Human 
PHC3 (80012) siRNA SMARTPOOL (L-015805-01-0005, Horizon Discovery) 
were used in paper II. 
 
In paper III, we used pre-designed siRNA: ON-TARGETplus Human KDM2B 
siRNA (J-014930-07, J-014930-08-0, Horizon Discovery) and also two siRNA 
which designed and ordered from ThermoFisher Scientific as below: 
 
KDM2B k1: GGCAGAAAGACTCTGGAAGAAGA (target on exon1) 
KDM2B k3: CAACTATGAGTACAGAGAGAA (target on exon3) 
Lipofectamine RNAiMAX Transfection Reagent (13778150, Thermo Fisher 
Scientific) was used to transfect CTCF siRNA (h) (sc-35124, Santa Cruz 
Biotechnology), GFP siRNA (sc-45924, Santa Cruz Biotechnology) or PARP1 
siRNA (h) (sc-29437, Santa Cruz Biotechnology) in HCT116 cell line in paper IV. 
 
3.5 RNA/DNA-FISH Analysis 
Bacterial artificial chromosome/clone (BAC) was used to generate probes for 
H19/IGF2, TLK1, VAT1L, PARD3, TARDBP, LADs and 4C interactors in Paper 
IV. The BACs probes were sonicated to 500-2000 bps range followed by labelling 
using Bioprime Array CGH kit (18095-011, Invitrogen). Equal amounts of each 
labelled products were used as FISH probe. 
 
In paper IV cells cultured on 8 wells chamber slides (154534, ThermoFisher 
Scientific) were crosslinked with 1 or 3 % formaldehyde for 15 minutes at room 
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temperature. The cells were permeabilized with 2X sodium salt citrate (SSC)/0.5% 
Triton for 10 minutes. The crosslinked slides kept in 70% Ethanol for storage at 
-20°C until further use. 
 
In DNA-FISH the crosslinked cells were denatured in 2X SSC/ 50% formamide 
(F9037, Sigma-Aldrich) for 40 minutes at 80°C, cells were kept in ice-cold 2X SSC 
(93017, Sigma-Aldrich) for 5 minutes. The FISH probe was mixed with human 
Cot-1 DNA (15279011, ThermoFisher Scientific) and hybridized to the slides in 
a buffer containing 10 % dextran sulfate sodium (D8906, Sigma-Aldrich), 2X 
SSC, and 50% formamide, overnight at 37°C. Cells were washed twice with 2X 
SSC/ 50% formamide for 15 minutes at 42°C and with 2X SSC for 15 minutes at 
42°C, and followed by mounting with Vectashield mounting medium containing 
4,6-diamidino-2-phenylindole (DAPI) (H-1200, Vector Labs). 
 
For RNA-FISH, without denaturation step at 80°C following hybridization and 
washing steps were performed as described before. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
  
4 RESULTS 
4.1 Study I 
Epigenetic regulators are essential for normal hematopoiesis, and they are involved 
in different well-known pathways such as self-renewal, proliferation, and dif- 
ferentiation. In this study, we aimed to investigate for new roles for epigenetic 
regulators in hematopoietic differentiation. We used a lentivirus construct Cas9- 
sgHPRT with blasticidin resistance to transduce K-562 cells and create stable 
K-562-Cas9 cells. K-562-Cas9 cells transduced with lentivirus library with 5048 
sgRNAs targeting 1092 epigenetic regulators plus 320 controls in duplicate. The 
transfected cells treated with Phorbol 12-myristate 13-acetate (PMA) for mega- 
karyocytic differentiation, and cells sorted after 72 hours of treatment for mega- 
karyocytic cell surface markers CD61/CD41 [130]. The morphological changes 
after PMA treatment studied by microscopy and phenotypic analysis carried out 
by flow cytometry. Three different gating settings used to collect different cell 
populations after PMA induced differentiation. We collected undifferentiated cells, 
which were negative for both CD61/CD41 markers (P1). The second population 
was double positive for both CD61/CD41 markers (P2). The last population was 
only positive for CD61 (P3). Two biological replicas sorted, and for each sample 
group, the genomic DNA sequenced for guides and UMI sequences. Each library 
analyzed in comparison with unsorted cells. The overlap for the top 10% of sgR- 
NAs selected if they were positive for all four sgRNAs and had log fold change 
more than 0.2 for each sgRNA. These criteria helped us to narrow our top gene list 
to 14 candidate genes in P1, 13 genes for P2, and 30 genes for the P3 population. 
One of the genes in the P3 population, called CHD2, belongs to the chromatin 
remodeler family, in which different members have been shown to be important 
for pluripotency in myeloid cells and also differentiation of muscle cells. 
For further validation of top candidates, in this study, CHD2 were knocked out in 
the same cell model (K-562) and differentiation treatment. For this part, we decided 
to use the CRISPR-Cpf1 system since it has higher efficacy and less off-target 
effects compare with CRISPR-Cas9. We designed four different sgRNA located at 
different exons in CHD2 (Exons 3, 7, 14, and 28) with the help of the Benchling 
web tool and cloned them into the vector pY095. The cloned vectors confirmed 
with Sanger sequencing. A mixture of all four sgRNA transfected to K-562 cells 
and in parallel, the original pY095 transfected as the control. After 72 hours, cells 
sorted for GFP signal and collected for single cells in 96 well plates. These single 
cells expanded and analyzed for CHD2 KO with western blot, and the knock out 
cells confirmed with Sanger sequencing for each specific exon. 
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The mono clones induced to differentiation treatment with the same protocol   
as the screen, but we used 24 hours treatment instead of 72 hours, to be able to 
detect earlier effects on differentiation. We validated that the CHD2 KO induced 
megakaryocytic differentiation by analysis differentiation after CHD2 KO, without 
PMA induction by comparing with the control samples. This data was in agreement 
with the results from the screen. The sgRNA targeting CHD2 enriched in the P3 
population. Hence CHD2 may have the potential to inhibit differentiation, which 
we confirmed in our single KO studies, demonstrating that CHD2 KO cells were 
more differentiated than control cells. Also, the CHD2 KO cells had a stronger 
differentiation response to PMA treatment in comparison with control cells, as the 
cell population for CD61/CD41 positive (P2) were significantly larger in com- 
parison to controls. To analyze whether the induced differentiation coupled with 
cell proliferation, the cells seeded in low cell density, and their logarithmic growth 
was followed every 24 hours for four days. Our comparisons showed that CHD2 
KO cells have a lower proliferation rate in low cell density conditions. Next, we 
decided to analyze the ability to form new colonies in our CHD2 knocked out 
cells in a colony-forming assay. Indeed CHD2 KO cells also have a lower ability 
to form colonies in CFU assays. 
Since RNA polymerase II is necessary for CHD2 recruitment to the active tran- 
scription start sites [131], we wanted to analyze the effect on transcription in CHD2 
KO cells. For this purpose, we used CHD2 CHIP-sequencing data for the K-562 
cell line from the ENCODE project to find CHD2-binding genes. We identified 
8872 CHD2 target genes. The G-ontology analysis showed that CHD2-target 
genes are involved in different cell functions, such as chromatin organization, 
histone modification, and cell cycle. In addition, we analyzed the K-562 CAGE 
data from the FANTOM 5 consortium, which showed that the expression level for 
CHD2-target genes is significantly higher in comparison with CHD2 non-target 
genes. To further determine the role of CHD2 on transcription, we performed 
RNA-sequencing on our CHD2 KO cells and controls. The RNA-sequencing data 
showed the importance of CHD2 in active transcription. CHD2 target genes were 
significantly repressed in CHD2 KO compare to the control cells. We also analyzed 
the role of CHD2 in AML patients in the Cancer Genome Atlas (TCGA) cohort 
for 162 de novo AML patients. Our analysis demonstrated a significant overlap 
between CHD2 co-expressed genes in AML patients and CHD2-target genes in 
K-562 cells. These data revealed that CHD2 might be involved to promote genes 
transcription in AML patients. 
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4.2 Study II 
Epigenetic modifiers and specifically the Polycomb repressive complex 1 and   
2 are essentials for cell lineage differentiation, and also self-renewal capacity   
in stem cells [132]. A lot of studies have been done to understand the functional 
roles of each PRC1 and -2, core subunits in their complexes and also in cellular 
developments. The Ring1A and Ring1B carry E3 ubiquitin ligase activity in the 
PRC1 complex, and in PRC2 complex EZH1-2 are responsible for trimethylation 
on histone H3 lysine 27 [60]. In this study, we focused on less-studied canonical 
subunits of PRC1 complex named Polyhomeotic homolog proteins (PHC) 1, 2 and 
3, and try to understand their potential roles in myeloid differentiation. 
We used publicly available datasets to analyze the differences between the expres- 
sion levels for all three PHC subunits during myeloid differentiation. The expression 
pattern differs between the subunits, with a high expression for PHC1 at the early 
stages of hematopoiesis, while expression levels for others two subunits are low. 
The expression levels for these subunits change during myeloid differentiation. 
 
We used the KG-1 cell line as a model to study the role of PHC1-3 in myelopoi- 
esis. It has been described that KG-1 can differentiate to monocyte/macrophage 
lineage at the presence of PMA [133]. So, the KG-1 cells underwent differentiation 
in the presence of 200 nM PMA for 48 hours, and differentiation confirmed both 
with morphology changes as well as increased level of the CD68 pan-macrophage 
surface marker expression. The only PHC subunits that showed changes at the 
mRNA level after treatment was PHC1. The PHC1 mRNA level was reduced by 
half approximately while there were no significant changes for PHC2 and PHC3. 
However, western blot data showed a reduction at the protein level for PHC1 and 
increased levels for PHC3 while we were unable to find a suitable antibody for 
PHC2. 
In the next step, we could establish an efficient and very specific knocked down 
system for each PHC subunit using pre-designed pool siRNAs, which gave more 
than 90% knock down for both PHC1 and PHC2 and around 60% for PHC3. The 
knocking down for each subunit was still stable after PMA differentiation for 48 
hours. The response to the PMA treatment was not strong enough and we only 
observed a trend in PHC2 KD sample. Our analysis for the expression level of 
CD68 mRNA showed an increased level after PHC2 KD. 
To explore the molecular mechanism for each PHC subunit during PMA differentia- 
tion, RNA-sequencing performed on each specific PHC subunit KD samples in the 
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presence of PMA (200 nM) for 48 hours. Our analysis showed different clustering 
for each set of PHC KD, which suggested that each subunit has distinct regulatory 
effects during differentiation, as well as shared gene targets in their downstream 
pathways. In our analysis, PHC2 showed the unique set of differentially expressed 
genes (2071 genes for PHC2 in comparison to 197 genes for PHC1, and 529 genes 
for PHC3), indicating that the different PHCs regulate specific gene sets. This pat- 
tern can be because of different knocked down efficiency in comparison to other 
samples, especially for PHC3, which needs to be improved. 
We performed the volcano plot analyzes for differential gene expression on RNA- 
sequencing data. The analysis confirmed the specificity of each PHC KD and 
showed the top differentially expressed genes for each sample against the control. 
 
Gene set enrichment analyses on the RNA-sequencing data demonstrated that 
despite being part of the same complexes, PHC1-3 regulate different pathways 
in myeloid differentiation, such as changes in the expression pattern of interferon 
response, myeloid developmental genes, HOXA9 targets, and EZH2 targets. EZH2 
is the catalytic subunit of PRC2 [134]. In our analysis, EZH2 target responses 
showed opposite regulation in PHC1 KD in comparison with PHC2 and PHC3 
KDs. Analyzing public data sets for both EZH1 and EZH2 expressions, we noticed 
these two subunits have almost the same level of expression in the hematopoietic 
stem cell in the bone marrow, but they switch their expression during differen- 
tiation. EZH2 expression level goes down with differentiation while, EZH1 has 
higher expressions in polymorphonuclear cells both in the bone marrow and the 
peripheral blood. 
To better understand the regulating mechanism underlaid PHC1-3 KD, we stud- 
ied the potential involvement of the canonical PRC1 complex. Both MEL-18 and 
BMI-1 are part of canonical subunits with PHC in the PRC1 complex. Taking 
advantage of publicly available data for CHIP-sequencing in K-562 cell line for 
both MEL-18 and BMI-1, and compared them with our gene list from each PHC 
1-3 KD. We showed a considerable overlap of PHC regulated genes and MEL-18 
BMI-18 target genes and pathways, which can indicate the common downstream 
pathways between these factors. 
 
 
 
 
 
 
 
 
 
30 
  
4.3 Study III 
Mammalian genome uses different mechanisms to diversify its transcript pool. 
Alternative splicing sites or alternative promoters are used in mammalians to 
produce multiple protein isoforms. It has been suggested that approximately half 
of the protein-coding genes have alternative promoters [135]. One of the critical 
steps to understand the regulation of gene transcription and development is to 
identify where the start site for a specific mRNA is located and how the isoforms 
are involved in the regulation of different developmental steps. 
In this study, we used the data from the FANTOM 5 database for transcription 
start sites (TSS) to investigate how the usage of alternative TSS can cause exclu- 
sion of coding sequence to regulate biological processes. We analyzed data from 
890 human primary cells cap analysis of gene expression (CAGE) libraries data 
from 176 different cell types. 
In the beginning, we decided on different controlling parameters to run our analy- 
sis. First, we overlapped different tags for each TSS and grouped them into tag 
clusters (TC) with an extra 500 bp from upstream; then we chose the TCs that have 
at least 1 or 10 tags per million (TPM) in any of the included cell types. Here we 
only focused on the TCs that have gene annotations. We had different hierarchi- 
cal filters to dissect all different TSS subclasses and their cellular specificity. We 
noticed that known TSS were commonly used in different cell types, but TSS in 
intragenic regions or antisense strands were more specific to the cell type. 
 
Then we re-run our analysis to find out if the TSS distribution were different across 
different cell types and identify outliners for each group. We notified that hemat- 
opoietic cells are among outliers in two groups with TSS in intragenic regions 
(10% instead of 6%) or protein-coding gene (20% instead of 39%). To dissect 
this finding more, we chose 11 primary hematopoietic libraries to characterize 
the usage percentage for each different TCs group. Our analysis showed that TCs 
within 5’ UTRs and known TSS in coding genes are more frequent in progenitor 
cells but not in the myeloid lineage. On the other hand, TSS within the coding 
region is more in favour of myeloid cells than progenitors. Besides, lymphoid cells 
showed preference pattern to somewhat in between progenitors and myeloid cells. 
These differences for TCs within protein-coding regions were interesting for us 
since this can cause truncated proteins with domain loss. In our analysis, 7.8% of our 
mapped TCs to known coding genes belonged to this group. Expression for some of 
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these TCs is highly cell-specific. Gene ontology analysis did not show any functional 
classification, although immune cells and blood cells showed a specific subgroup. 
Then we decided to explore the definition of an alternative promoter, as it is com- 
monly believed the most upstream TSS is the main TSS, but our analysis showed that 
this is the case for only 33% of the TCs in our libraries. Our analysis showed that 
the most upstream promoter used ubiquitously, but it is not the specific promoter. 
Using the FANTOM 5 data, we could show that alternative TSS to transcribe Vinexin 
utilized in different cell types. Also, other studies have shown that different protein 
variants, of vinexin alpha and beta, have cell type specific functions [136-138]. 
 
To investigate the functional impact of the protein isoforms that generated from 
alternative TSS, we set some parameters to find TCs, which leads to domain loss in 
specific cell types. These analyses showed that 78 protein domains from 36 genes 
have alternative TSS that cause a protein domain loss. When we did our analysis 
only on the hematopoietic cells, we could show the domain loss happens in 60 dif- 
ferent proteins based on lineage or cell-type-specific. Focusing on epigenetic and 
transcriptional regulators, we validated the alternative TSS in KDM2B, PRDM1, and 
RERE, with real-time PCR data, performed in different hematopoietic cell types. 
 
We continued to investigate the role of different TSS on KDM2B isoforms in Jurkat 
cells since the mice studies have confirmed there are two Kdm2b isoforms, and we 
speculated it might also be the case in human. We targeted the two most expressed 
TSSs (TSS1 and TSS3) for KDM2B with specific siRNA for knocking down and 
investigate the functional outcomes for knocking down different isoforms with 
RNA-sequencing and CHIP-sequencing. Our analysis revealed differences between 
two isoforms, with the importance of the long isoform in transcription regulation, 
while almost no transcriptional effects from knocking down the short isoform. The 
H2AK119ub CHIP-sequencing data showed the same results. 
In the end, we followed the changes in domain usage during cell differentiation. 
In this part, we looked at 16 different time courses, and our analysis showed 76 
different genes that have a change in their TSS activity for short and long isoforms, 
which some of them are even novel. 
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4.4 Study IV 
In this study, our goal was to understand how chromatin organization in 3D in 
different sub-nuclear compartments impacts transcriptional regulation. To answer 
this question, we performed circular chromatin conformation capture (4C) coupled 
to sequencing [139] to the well-studied epigenetically regulated H19 imprinted 
control region (ICR) [140]. We used this region as a bait in human embryonic 
stem cells (hESCs) and derived human embryoid bodies (hEBs). We identified 
518 different intra- and inter-chromosomal chromatin fiber interactions. These 
interactions within the network were later confirmed by 3D DNA-FISH analysis, 
showing that interactors with high reads counts in the 4C-seq were significantly 
closer to the main bait (i.e., H19 ICR and VAT1L) compared with regions with 
the lower number of reads. 
Given the unique capacities of our 4C assay to capture more than two simulta- 
neously interacting sequences, we could reconstruct the interactions between the 
interactors of the H19 ICR to define a network of interactions within our bait. We 
then reasoned that regulated encounters within the network might be facilitated by 
dynamic molecular ties. As we previously showed that PARylation of CTCF was 
essential for the long-range chromatin insulation in cis [141], we decided to test 
if it was also necessary to form chromatin network interactions in trans. Our data 
showed that the removal of PAR by PAR glycohydrolase (PARG) activity led to 
the disassembly of the majority of the chromatin networks. In parallel, and since 
CTCF can activate PARP-1 [142], we observed a reduction of PAR levels upon 
CTCF knock-down, suggesting that PARylation in chromatin complexes might 
be the result of CTCF and PARP-1 interactions. 
We hypothesized that genomic loci occupied by PARP-1 formed dynamic com- 
plexes with other chromatin regions that carried factors binding to PAR with high 
affinity such as CTCF. To prove that we treated hESCs with the PARP-1 inhibitor, 
Olaparib, which not only inhibits PARP-1 activity but also disrupts the interaction 
between PARP1 and CTCF, for 24 hours. Our results showed that Olaparib treat- 
ment led to a significant reduction in the proximity between chromatin network 
hubs under these conditions. Our results also showed that the interaction between 
CTCF and PARP1 is crucial for the connection between H19 ICR and its inter- 
acting chromatin network. 
Because it was previously shown that PARP-1 activity oscillates by feeding [143]. 
Our analysis in the 4C library showed interactions between LADs and circadian 
controlled genes. We decided to investigate whether our network represented 
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some fine-tune mechanism of regulation of circadian genes. We could not estab- 
lish circadian synchronization in hESCs as it was reported before [144], nor in 
hEBs because of their production procedures. Instead, we used the human colon 
cancer cell line HCT116 cells as an appropriate model for circadian synchroniza- 
tion upon serum shock [145]. Data from in situ proximity ligation assay (isPLA) 
revealed that CTCF and PARP-1 proximity oscillates in a circadian manner, with 
peaks of interactions at 8 and 32 hours after serum shock, and mainly occurring at 
the nuclear periphery. Additionally, 3D DNA-FISH analysis for our 4C bait (IGF/ 
H19 ICR) and circadian network nodes (VAT1L, TARDB,P and PARD3) showed 
a rhythmic pattern of recruitment of these loci to the repressive environment of 
the nuclear periphery which correlates with oscillating transcriptional attenuation 
(RNA-FISH analysis). A more detailed examination of the PARD3 locus with a more 
detailed kinetics between 8 and 16 hours after serum shock revealed that following 
the arrival to the nuclear periphery at 10 hours, the transcription attenuation of 
this locus occurred later, between 10 and 12 hours, together with the acquisition 
of the repressive chromatin mark H3K9me2, investigated by assessing the prox- 
imity between this hPTM and the PARD3 locus by chromatin in situ proximity 
analysis (ChrISP) [146]. The importance of H3K9me2 acquisition in circadian 
transcription was further proved by showing that upon its depletion by inhibiting 
the methyl transferase G9a/Glp, PARD3 recruitment to the nuclear periphery and 
its transcriptional circadian oscillation were abolished. Thus, we concluded that 
circadian recruitment of active alleles to the nuclear periphery preceded the acqui- 
sition of the H3K9me2 repressive mark and circadian transcriptional attenuation. 
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5 DISCUSSION 
Although the genome of different cells in an organism is the same, different regu- 
latory mechanisms are involved to allow different transcriptomes from the same 
genetic material at the different developmental stages and differentiation levels. 
The epigenetic machinery and its impact on the genome and transcription levels 
are the most critical parts of the regulatory mechanisms. 
To study different parts of the epigenetic machinery, we took advantage of the hemat- 
opoietic system in studies I-III. One of the main reasons for that is the frequently 
mutated status for epigenetic regulators in hematological malignancies [147]. 
 
5.1 Study I 
In this study, we could show that our CRISPR-Cas9 library was an efficient method 
for study epigenetic regulators in the hematopoietic system. In our analysis on 
CRISPR-Cas9 library for 1092 epigenetic factors, we were not only able to iden- 
tify new regulators but also reconfirm the regulatory role for some of the previ- 
ously published epigenetic factors, such as ARID4B, KMT2A/MLL, and ASH1L. 
In total, we could show a potential regulatory role for approximately 5% of our 
library (57 epigenetic factors). With our analysis, we also revealed a potential 
new regulatory role for some of the epigenetic factors in human hematopoiesis 
differentiation pathways. 
In our analysis, chromodomain helicase DNA-binding 2 (CHD2) was among our 
top genes on the list that we selected to validate with further analysis to show its 
role in megakaryocytic differentiation. Recently, other members of the chromodo- 
main helicase DNA-binding family has shown to be important in the pluripotency 
of stem cells and also the progression of childhood AML [148,149]. It has already 
been shown that Chd2 can regulate muscle differentiation [150]. The genome-wide 
analysis showed that MyoD transcription factor is dependent on Chd2 for H3.3 
deposition into specific gene promoters that induce muscle differentiation [150]. In 
our previous study, we noticed that the involvement of CHD2 in H3.3 deposition 
is not specific to the muscle cells, but also in myeloid cells [131]. Additionally, 
we showed in the K-562 cell model that both CHD1 and CHD2 participate in 
regulating the chromatin architecture in transcribed active loci. RNA-polymerase 
II is involved in their recruitment [131]. 
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In this study, we demonstrated that CHD2 knocked out in the K-562 cell line 
promotes megakaryocytic differentiation and inhibits cell proliferation. This data 
suggested that CHD2 is important to inhibit megakaryocytic differentiation. Our 
data for CHD2 KO in K-562 is in concordant with data from Chd2 KO in mice. 
It has shown that Chd2 is an essential gene for development and survival. The 
Chd2 KO mice have a deficiency in hematopoietic stem cell differentiation, which 
leads to lymphomas [151]. 
Our analysis of the ENCODE data revealed that CHD2 could affect transcription 
via the Polymerase II machinery. RNA-sequencing data on our CHD2 KO cells 
confirmed the role of CHD2 in transcription specifically for CHD2-target genes. 
 
Our data clarify that CHD2 is important for proliferation, and its loss of function 
can promote megakaryocytic differentiation in K-562 cells. 
 
5.2 Study II 
Different studies have shown that PRC complexes are crucial for gene silencing 
and regulation of hematopoietic differentiation, and try to dissect the roles for 
different PRC complexes subunits in hematopoiesis [36]. This study aimed to 
investigate the role of the different Polyhomeotic homolog proteins (PHC) sub- 
units in the PRC1 complex during hematopoietic differentiation. Our analysis of 
publicly available data suggested reverse regulatory roles for different PHC1-3. 
This pattern confirmed with our PHC knock down and RNA-sequencing experi- 
ments. Our data showed several potential genes and pathways, which are important 
for PRC1 complex functions in general and, more specifically, for PHC subunits. 
We believe that further experiments are needed to improve our data and clarify 
the potential regulatory roles for different PHC subunits. One way to do it, is to 
use a more efficient knock down system, and obtain stable knocked down cells. 
This issue is especially for PHC3 that had only around 30 folds down regulation 
in comparison to 50 and 150 folds for PHC1 and PHC2, respectively. We tried to 
use the CRISPR-Cpf1 system to knock out each PHC subunit in KG-1 cells, but 
the cells did not survive after transfection. We will investigate the PHC roles with 
shRNA (short-hairpin RNA) for each specific PHC subunit in our KG-1 model. 
The construction for specific insertion into the lentiviral vector is ongoing. 
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5.3 Study III 
The technical development in RNA-sequencing such as cap analysis of gene 
expression (CAGE) allowed to profile gene expression with a focus on 5’ end, and 
allowed a better understanding for transcription start sites (TSS) [152]. Intensive 
CAGE data analysis revealed lots of new TSSs and alternative promoters [153]. 
In this study, we demonstrated that different human cell types are using a similar 
fraction of TSSs except in immune and blood cells that have different TSS usage. 
As mentioned before, in the progenitors: 5’ UTR and known TSS in coding genes, 
in the myeloid cells: TSS within coding genes are frequent, and the lymphoid pat- 
tern is in between the progenitors and myeloid cells. 
In our analysis, we have noticed two occurring patterns for alternative TSS. As the 
case for NFXL1, the alternative TSSs can help to have different isoforms with dif- 
ferent repeats of individual domains, which can help with the protein function and 
its efficiency. Another pattern can be like what we saw for MY010; the alternative 
TSSs can cause different isoforms with domain loss and have a regulatory effect. 
 
KDM2B was among the genes with domain loss in hematopoietic cells. Published 
studies in mice also support this finding. However, our functional studies were 
unable to demonstrate specific roles for different KDM2B TSSs and its potential 
isoforms. 
 
This study revealed a novel phenomenon of alternative TSS usage of genes accord- 
ing to hematopoietic differentiation. Although, as with all RNA-based studies, 
the mRNA isoforms need to prove also to become translated to protein isoforms. 
We were unable to confirm the existence of protein isoforms for KDM2B due to 
the technical problems with antibodies and further experiments for confirmation 
are needed. However, our results still inspire the further exploration of epigenetic 
regulation mediated by KDM2B isoforms during differentiation. 
 
5.4 Study IV 
Chromatin has active and inactive domains. Their transcriptional status is prone 
to segregate into distinct sub-nuclear compartments so they can maintain their sta- 
ble expression patterns. In paper IV, we demonstrated that an inter-chromosomal 
network emerging from hESCs and derived hEBs connects active loci enriched in 
circadian genes to transcriptionally repressed lamina-associated domains (LADs). 
PARP1 and its co-factor CTCF regulate this interactome. The association between 
these two proteins does not only mediate chromatin fiber interactions but also 
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assist the recruitment of circadian genes to the nuclear lamina. Serum shock in 
HCT116 colon cancer cells induced synchronization. This synchronization promotes 
oscillations in PARP1-CTCF interactions and followed by oscillating recruitment 
of circadian loci to the lamina. The repressive H3K9me2 marks acquisition and 
transcriptional attenuation followed. Additionally, H3K9me2/3 depletion by inhi- 
bition of PARP activity with Olaparib, inhibiting G9a/Glp, or down regulation of 
PARP1 or CTCF expression not only counteracts with recruitment to the nuclear 
envelope but also circadian transcription. PARP1- and CTCF can regulate inter- 
actions between circadian loci and the repressive chromatin environment at the 
nuclear lamina, as a result, moderate circadian transcriptional plasticity. 
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call you Dr. LiLi, Christmas always reminds me of you and our memories in the 
lab. After all, it was my first Christmas and we had the opportunity to be alone in 
the whole department! Gözde, I have changed this part so many times depending 
on your visa situation and different factors! But you know who you are and you 
have already said enough in your book, so I am not going to repeat them. You can 
check it in your thesis. Manos, we still need to discuss a bit more about history :) 
Lluis, it was a great time to work with you and thanks for all your help when we 
were working in the same lab. Carolina, although the first time I saw you were 
in the darkness of the microscope room, you were with me during my times of 
happiness and also sadness. Thank you for your true friendship and even more. 
Barbara, I am so happy to have the chance to work with you and I am even more 
happy to have you as a friend now. Richelle, it was fun to teach you lab works 
and thanks for helping me to learn more. Aga, it was fun to work with you and 
trying to solve all the troubles with the microscope or different protocols. Hope 
to see you and Bartek soon ;) Vanessa, thanks for speaking not very British and 
in a way that we could understand and let us think our English was improving! 
Good luck with your studies. Alisa, it was fun to be your co-supervisor for your 
master thesis and I learned a lot during that time. I am happy for you and your 
Ph.D. journey! Mirco, we didn’t spend so much time in the lab but I am happy to 
know you and be your friend, despite disagreeing with each other 95% of the time 
:) Ilias, it was fun to teach you how to work with the microscope when you had 
just joined the lab. Johana, we never had the chance to work together but thanks 
all the unforgettable memories especially, from Gotland. 
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Andreas, Huma, and Nancy I had so much fun in Novum when we were sharing 
an office. Thanks for all the different topics and discussions during coffee time. 
Fatemeh, thanks for all the talks and encouragement while we were almost shar- 
ing the office with you but without seeing each other thanks to those thin walls ;) 
My friends at BioNut: Marjan, when should we go to the gym? Although this 
question is more about me!!! You are my motivator! Yasaman, I hope the cake 
for my party for once will be the one that I asked for! I am going to miss you girls. 
Thanks for all the memories during dinners, coffee breaks, and birthday parties. 
You made my life full of fun. Thanks for being who you are so I can talk to you 
when I needed it. Thanks in advance for all the help with my dissertation and 
the party. Marjan, thanks for accepting to be the toastmaster, just don’t forget to 
make the music playlist :) Alex, thanks for all the discussions during lunchtime 
and practicing Swedish on Wednesdays’ lunchtime. Lisa and Jenna, thanks for 
all the shared memories during your time in the BioNut. Parisa, we always need 
your help to cut the cakes in the end to a good shape; after all, there are so many 
edges and we need to get rid of them! You are a lifesaver! Mohammad, thanks for 
all the discussion and your help with eating chocolates and cookies in the office 
;) Laia, thanks for never forgetting us when you went home and always bring- 
ing the best gifts that we could ever ask for --the familiar taste of Iranian sweets 
;) Marzieh, good luck with the new job! Olga, it was so funny how you learned 
one Persian phrase (Mage chie?!) and almost could use it in the best moments :) 
Lina, thanks for all your kind support, especially when I need something urgent 
in the lab. Vlad, thanks for being so patient when the girls and I were talking in 
secret and you somehow always found out what the plan was about ;D Serena, 
thanks for all the chats and encouragement. You are the best partner for carving 
a pumpkin for Halloween :) Ani, thanks for all the discussions and encourage- 
ment. Jonathan, thanks for all the discussions in the cell culture room ;) Leticia, 
you should come back and help me solve my biggest dilemma from our Swedish 
class, after all which one is correct: Aja Baya or Aja Paya! Tales, thanks for all 
the fun in the Base. Agustin, thanks for all encouragement and reminders to write 
my thesis ;) Su, good luck with the rest of your study. 
My friends at HERM: Shabnam, you are no longer with us in Stockholm, but 
this doesn’t change anything. I am always looking forward to seeing you and 
thankful for your friendship. Esmat, it was so great to meet you in Stockholm.  
I am always missing you and your big heart, but then I am happy to have you in 
my life. Jelveh, you are such a kind person that talking for a short time in a cor- 
ridor always helps lift my spirit. Thanks for all your help. Nadir, thanks for all 
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your advice on not making mistakes in science and my life that I could not fol- 
low them most of the time ;) and also for not putting my name on the blocked list 
on your phone! Teresa, thanks for your help and for teaching me CFU protocol. 
Thuy, thanks for all dinners and game nights. Monika, good luck with the new 
job. Lakshmi, thanks for all the encouragement and chats especially close to the 
ice machine :) Saeid, thanks for your kind scientific advice. Mahin, thanks for 
all your kindness and help. 
My CHaSE friends: Zack, Azadeh, Kai, Natali, Kadir, Yan, Maryam, Josefin, 
and Vanja, I am so happy to get to know all of you and learned a lot during all 
those meetings and discussions. I think we did great work at CHaSE 2019. 
 
My old friends at MTC, especially Habib, Mariam, Afrouz, Sunitha, thanks 
for all the MSA board meetings. It was fun to skip the lab at that time even for a 
short time. It is even more joyful to see you now when it happens. Tomek, when 
should we start working on our space shuttle :D 
My friends in KI and especially those who I know from my time in KI housing in 
Varberg, it is always fun to see you either in a party or international dinner or just 
to meet you in different corridors and buildings in KI: Karen, Yogan, Tomek, 
Fadwa, Rita, Jorge, Laetitia, Lorena, Mellina, Naida, Mike, Shane, Avinash, 
Sunjay, Caitrin, Yildiz. 
 
It was impossible for me to work over the last eight years without having new 
friends in my life. Most of them are like a family to me and I love you all. Sonia and 
Henric, I am so lucky to have you in my life. Going to different Swedish classes 
didn’t help me learn it, but it certainly helped me find one of my best friends who 
is more like a sister to me. Henric, now that I have a Ph.D. in Biology you should 
trust me more with my knowledge about animals. It is a panda’s picture on the 
wall--not a koala! Let’s not forget the little Lionel-Nivan and how much joy he 
brought to our life with so many sleepless nights! Misia and Samer, thanks for 
your true friendship during all these years. It is a journey to the middle of nowhere 
to come and visit you, but once there, it is always fun thanks to Ada and Vincent 
:) Ania and Uffe, I am always amazed every time I come to your place for a visit. 
There are always so many changes and progress with the house renovations, how 
you are managing? Let’s not forget how much I enjoyed playing with Daniel and 
David and how much I tried to improve my Swedish with them. Not that they ever 
approved :) Moumita and Punit, thanks for all those spicy foods and I hope to 
see you soon and hopefully it will be in India or somewhere else. The world is so 
 
 
 
44 
  
small after all! Fatima and Jake, it is sad that you live in Bergen, but it makes it 
really fun for me to travel there and spend time with you especially when Jake is 
cooking ;) Thanks for all the video calls and your support during all these years. 
As always, I look forward to seeing you soon ;) Caro and Frans, I am so lucky to 
have you in my life and it is always great to be able to join your family gatherings 
and spend time with you all. Let’s not forget the little Olivia and fun time with 
her :) Andres, thanks for being a good friend and also a good listener that I can 
tell everything and nag about anything. You know how much I love you! Anu, 
thanks for being a good friend and always late, so giving me a reason to nag about 
something to Andres: why is Anu never on time!!! :) 
Iranian friends in Sweden: Hanna and Amir, thanks a lot for not only being my 
friends but also my family here in Sweden. Big thanks to Hanna for all those spe- 
cial Tahdig and foods that never let me feel homesick. Thanks for teaching me the 
basic lessons for Persian cooking and the difference between different spices and 
how to use them! Amir, thanks for not pretending to eat whatever I cooked and 
always asking me not to cook, although I never listened, but only tried to cook bet- 
ter! A big thanks to Abtin for teaching me dinosaurs’ names, but I always needed 
a reminder. After all, I can’t know and remember everything in biology! Suzan, I 
am so lucky to have you in my life and for letting me be part of your family. For 
all the Yalda’s night, shopping for Norouz, movie nights, phone calls, and your 
endless kindness and smile. You know how much I love you. Sahar, thanks for 
your friendship and your big smile. Mehrdad, thanks for all those times that we 
either watched movies or discussed them. We can’t watch them together now that 
you live in Canada, but I still enjoy catching up in our next discussion. I just wish 
you had more skills to play a game just like me :) Sareh, thanks for your friendship 
and all the encouragement. You are the next to defend! Sadna and Reza, thanks 
for all the fun memories, especially during all the 13bedars and BBQ ;) Khalil 
and Santa, thanks for your friendships and all the fun times with your BBQ skills. 
Atefeh, Daniel, and Hamid, thanks for all the fun and game nights. Hadis and 
Mehdi, thanks for all your kindness and friendship. Marzieh, and Shahla thanks 
for all the fun memories and dinner times. Manizhe and Yaser, thanks for your 
true friendship. Meeting you again in Stockholm was a big gift for me especially 
when we were living in the same building and you were helping me with all of my 
cooking and baking ;) Yasi Golab and Behrooz, your friendship are an inspiration 
to me with all of your traveling and adventures tips. I never forgot our memories 
from Gran Canaria :) Maryam, it was fun to be in Swedish class with you. At 
least I could practice Persian with you! Thanks for being so understanding during 
these last few months with all the applications and forms. Soon it will be your 
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time, so good luck! Amir, thanks for all the time that we have spent on the road, 
either on a bike or a car! Anahita and Peyman thanks for your friendship and 
enjoyable times, especially with your cute boy. Azi and Maryam, it was my luck 
to meet you, thanks for all the laughs and fun time. Azi, keep doing what you do 
and soon it is going to be your time to graduate. 
I can’t finish this part if I don’t mention some of my friends’ names that although 
we couldn’t see each other as much as we would have liked, you all will always 
be a part of my life no matter where I live. You all helped me have a better life and 
gave me energy and motivation with your endless video calls, emails, messages 
and meeting you whenever we could be in the same place. Mahshid, thanks for 
all the encouragement during all the time that I’ve known you and for the best 
memories from Italy. I hope to see you soon. Fereshteh, you have taught me a big 
lesson: to follow my happiness and leave a place when it doesn’t make me happy. 
Also, thanks for showing me to take risks and also letting me risk my life with your 
driving ;) Saeide, Faezeh, Nina, Simin, Shahla, Zahra, Maryam, Elahe, Roya, 
Sohila, Fahimeh, and Zahra thanks for your true friendship during all these years. 
For checking on me with your messages and emails, especially thanks for when I 
come back to visit and treating me as a tourist ;) Mahboobeh, and Hoda thanks 
for all those memories and thanks for still keeping in touch with me. Mahboubeh, 
thanks for all of your support in teaching me the basics of molecular biology when 
I was a Master’s student, for helping me to find my Ph.D. position and for all your 
encouragement during these years. 
Maryam, I don’t have a word to describe how much I missed you during these 
years, but thanks for always being there for me when I need someone to listen to 
me nag or complain. After all, you know me very well. Mohammad and Davood, 
thanks for all the fun times and especially dancing time when I am back home and 
not on a road! Behnaz, you are my oldest friend and it is too bad that we can’t see 
each other as often, but thanks for always sending me pictures so old that even I 
have trouble identifying myself. You are always there for me with some nostal- 
gia brought on by old memories. Love you and both your kids. Naiereh, you are 
as dear to me as Behnaz, thanks for accepting me into your family. Ghazal and 
Peter, thanks for your hospitality during my visit to Montreal and I hope to see 
you soon :) Mohadeseh, I will never forget how we met and how I didn’t like 
you in the beginning--or it was you who didn’t like me! Either way, you are one 
of my dearest friends now. We missed so many events over these years due to the 
distance, but nothing can change our friendship --even your constant problems 
with your phone or your internet! I want to see Haana. Thanks to her we almost 
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have the same birthdate and now you can’t say you forgot my birthday anymore! 
Najmeh, what can I say about you? Sometimes you are the only way that I can get 
some news from Mohadeseh when she has one of her problems with her phone, 
so thanks for being a good messenger ;) Neda, thanks for not only being a great 
teacher to me but also a good friend. I will never forget that you gave me my very 
first book in genetics. All my troubles started from that day! Just kidding ;D 
My dearest Setareh and Mohsen. I have learned a lot by being your student. You 
were great mentors when I was an undergraduate student and those times in the 
Genetic Consulting Center were some of the best times in my life. I have learned 
so many life lessons in that center. Thanks for all your support and advice during 
all these years. I was so lucky to meet you in Toronto and I hope to see you soon. 
Hopefully, this time we will reunite in Stockholm :) 
 
Last, but not least, I would like to thank my family. No matter how far I go they are 
always there for me. Sohila, from the time that you joined our family you brought 
lots of joy and happiness with you. After all, you are the sister that I never wanted, 
but now are forced to have and I have to love you more than my brothers since it 
is the sister-code! Let’s not forget the newest family member, my little nephew, 
Kourosh. Unfortunately, I haven’t been able to witness firsthand how much you 
are growing, but I am happy you have Sohila as your mom so she can teach you 
how to live your life while the rest of the family, including me, tries to spoil you ;) 
Bahram, you are more than a big brother for me and I cannot express how much 
I love you! Bahman, what can I do, you are the last kid so I have to love you 
maybe a little more than Bahram. I love you both from the bottom of my heart. 
I thank both of you for making my childhood full of joy, playfulness, and fights 
until death! Thanks for all of your support and for being my wings until I learned 
to fly. Thanks for being such good brothers that I never wanted to have a sister. I 
can’t tell you how lucky I am to have you both in my life even if you are far away 
from me :) Shekoofeh and Khalil, thanks for being my parents and teaching me 
how to live without any fears or barriers. Thanks for forcing me to have big dreams 
and letting me fight for them! You are the reason that I am always going far to try 
to be a better version of myself. 
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